G. Köhler and C. Milstein, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, vol.256, issue.5517, pp.495-497, 1975.

D. M. Goldenberg, F. Deland, E. Kim, S. Bennett, F. J. Primus et al., Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning, New England Journal of Medicine, vol.298, issue.25, pp.1384-1388, 1978.

S. J. Denardo, G. L. Denardo, L. F. O'grady, D. J. Macey, S. L. Mills et al., Treatment of a Patient with b Cell Lymphoma by 1-131 Lym-1 Monoclonal Antibodies, The International Journal of Biological Markers, vol.2, issue.1, pp.49-53, 1987.

O. W. Press, J. P. Leonard, B. Coiffier, R. Levy, and J. Timmerman, Immunotherapy of Non-Hodgkin's Lymphomas, Hematology, vol.2001, issue.1, pp.221-240, 2001.

B. D. Cheson, Radioimmunotherapy of non-Hodgkin lymphomas, Blood, vol.101, issue.2, pp.391-398, 2003.

D. M. Goldenberg and R. M. Sharkey, Recent progress in cancer therapy with radiolabeled monoclonal antibodies, Therapeutic Delivery, vol.2, issue.6, pp.675-679, 2011.

J. Pouget, I. Navarro-teulon, M. Bardiès, N. Chouin, G. Cartron et al., Clinical radioimmunotherapy?the role of radiobiology, Nature Reviews Clinical Oncology, vol.8, issue.12, pp.720-734, 2011.
URL : https://hal.archives-ouvertes.fr/hal-02962928

A. R. Snyder, Review of radiation-induced bystander effects, Human & Experimental Toxicology, vol.23, issue.2, pp.87-89, 2004.

J. M. Brown and A. J. Giaccia, The unique physiology of solid tumors: opportunities (and problems) for cancer therapy, Cancer Res, vol.58, issue.7, pp.1408-1424, 1998.

M. A. Konerding, E. Fait, and A. Gaumann, 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon, British Journal of Cancer, vol.84, issue.10, pp.1354-1362, 2001.

P. A. Netti, L. M. Hamberg, J. W. Babich, D. Kierstead, W. Graham et al., Enhancement of fluid filtration across tumor vessels: Implication for delivery of macromolecules, Proceedings of the National Academy of Sciences, vol.96, issue.6, pp.3137-3142, 1999.

M. Tabrizi, G. G. Bornstein, and H. Suria, Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease, The AAPS Journal, vol.12, issue.1, pp.33-43, 2009.

G. M. Thurber, M. M. Schmidt, and K. D. Wittrup, Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance, Advanced Drug Delivery Reviews, vol.60, issue.12, pp.1421-1434, 2008.

F. M. Chen, A. L. Epstein, Z. Li, and C. R. Taylor, A comparative autoradiographic study demonstrating differential intratumor localization of monoclonal antibodies to cell surface (Lym-1) and intracellular (TNT-1) antigens, J Nucl Med, vol.31, issue.6, pp.1059-66, 1990.

J. Chatal, F. Davodeau, M. Cherel, and J. Barbet, Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors, Journal of Cancer Research and Therapeutics, vol.5, issue.9, p.36, 2009.

B. Collins-burow and E. S. Santos, Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma, Expert Review of Anticancer Therapy, vol.7, issue.3, pp.257-273, 2007.

T. Bäck, B. Haraldsson, R. Hultborn, H. Jensen, M. E. Johansson et al., Glomerular Filtration Rate After Alpha-Radioimmunotherapy with 211At-MX35-F(ab?)2: A Long-Term Study of Renal Function in Nude Mice, Cancer Biotherapy and Radiopharmaceuticals, vol.24, issue.6, pp.649-658, 2009.

H. Andersson, E. Cederkrantz, T. Back, C. Divgi, J. Elgqvist et al., Intraperitoneal -Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab')2--A Phase I Study, Journal of Nuclear Medicine, vol.50, issue.7, pp.1153-1160, 2009.

K. Lam, C. Chan, and R. M. Reilly, Development and preclinical studies of 64Cu-NOTA-pertuzumab F(ab?)2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT, mAbs, vol.9, issue.1, pp.154-164, 2016.

M. Ueda, H. Hisada, T. Temma, Y. Shimizu, H. Kimura et al., Gallium-68-Labeled Anti-HER2 Single-Chain Fv Fragment: Development and In Vivo Monitoring of HER2 Expression, Molecular Imaging and Biology, vol.17, issue.1, pp.102-110, 2014.

, Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy, Diagnostics, vol.7, issue.2, p.26, 2017.

M. Shadman, H. Li, L. Rimsza, J. P. Leonard, M. S. Kaminski et al., Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016, Journal of Clinical Oncology, vol.36, issue.7, pp.697-703, 2018.

A. Martínez, M. Martínez-ramirez, D. Martínez-caballero, P. Beneit, J. Clavel et al., Radioimmunotherapy for non-Hodgkin's lymphoma: positioning, safety, and efficacy of 90Y-ibritumomab. 10 years of experience and follow-up, Revista Española de Medicina Nuclear e Imagen Molecular (English Edition), vol.36, issue.1, pp.13-19, 2017.

A. Martínez, M. Martínez-ramirez, D. Martínez-caballero, P. Beneit, J. Clavel et al., Radioimmunotherapy for non-Hodgkin's lymphoma: positioning, safety, and efficacy of 90Y-ibritumomab. 10 years of experience and follow-up, Revista Española de Medicina Nuclear e Imagen Molecular (English Edition), vol.36, issue.1, pp.13-19, 2017.

B. Cahan, L. Leong, L. Wagman, D. Yamauchi, S. Shibata et al., Phase I/II Trial of Anticarcinoembryonic Antigen Radioimmunotherapy, Gemcitabine, and Hepatic Arterial Infusion of Fluorodeoxyuridine Postresection of Liver Metastasis for Colorectal Carcinoma, Cancer Biotherapy and Radiopharmaceuticals, vol.32, issue.7, pp.258-265, 2017.

S. Vallabhajosula, A. Nikolopoulou, Y. Jhanwar, G. Kaur, S. Tagawa et al., Radioimmunotherapy of Metastatic Prostate Cancer with <sup>177</sup>Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody, Current Radiopharmaceuticals, vol.9, issue.1, pp.44-53, 2015.

F. Kraeber-bodéré, C. Rousseau, C. Bodet-milin, L. Ferrer, A. Faivre-chauvet et al., Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial, J Nucl Med, vol.47, issue.2, pp.247-55, 2006.

J. S. Batra, B. Karir, K. Pinto-chengot, Y. S. Jhanwar, S. Vallabhajosula et al., MP50-19 DOSE-FRACTIONATED ANTI-PSMA RADIOIMMUNOTHERAPY ( 177 LU-J591) FOR MCRPC, Journal of Urology, vol.195, issue.4S, p.680, 2016.

A. Capello, W. A. Breeman, B. Bernard, M. De-jong, and E. P. Krenning, Peptide Receptor Radionuclide Therapy: Preclinical Findings, Radionuclide Peptide Cancer Therapy, vol.44, pp.127-143, 2016.

J. A. O'donoghue, M. Bardiès, and T. E. Wheldon, Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides, J Nucl Med, vol.36, issue.10, pp.1902-1911, 1995.

M. R. Zalutsky, D. A. Reardon, G. Akabani, R. E. Coleman, A. H. Friedman et al., Clinical Experience with -Particle Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6, Journal of Nuclear Medicine, vol.49, issue.1, pp.30-38, 2007.

P. Bhusari, R. Vatsa, G. Singh, M. Parmar, A. Bal et al., Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients, International Journal of Cancer, vol.140, issue.4, pp.938-947, 2016.

M. Kameswaran, U. Pandey, C. Dhakan, K. Pathak, V. Gota et al., Synthesis and Preclinical Evaluation of 177Lu-CHX-A?-DTPA-Rituximab as a Radioimmunotherapeutic Agent for Non-Hodgkin's Lymphoma, Cancer Biotherapy and Radiopharmaceuticals, vol.30, issue.6, pp.240-246, 2015.

W. C. Eckelman, C. H. Paik, and R. C. Reba, Radiolabeling of antibodies, Cancer Res, vol.40, issue.8, pp.3036-3078, 1980.

A. E. Bolton and W. M. Hunter, The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. Application to the radioimmunoassay, Biochemical Journal, vol.133, issue.3, pp.529-538, 1973.

A. T. Yordanov, K. Garmestani, M. Zhang, Z. Zhang, Z. Yao et al., Preparation and in vivo evaluation of linkers for 211 At labeling of humanized anti-Tac, Nuclear Medicine and Biology, vol.28, issue.7, pp.845-856, 2001.

S. Liu, Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides, Advanced Drug Delivery Reviews, vol.60, issue.12, pp.1347-1370, 2008.

K. Fujiki, S. Yano, T. Ito, Y. Kumagai, Y. Murakami et al., A One-Pot Three-Component Double-Click Method for Synthesis of [67Cu]-Labeled Biomolecular Radiotherapeutics, Scientific Reports, vol.7, issue.1, pp.1912-1921, 2017.

M. Frindel, N. Camus, A. Rauscher, M. Bourgeois, C. Alliot et al., Radiolabeling of HTE1PA: A new monopicolinate cyclam derivative for Cu-64 phenotypic imaging. In vitro and in vivo stability studies in mice, Nuclear Medicine and Biology, vol.41, pp.e49-e57, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01529578

J. M. Bennett, M. S. Kaminski, J. P. Leonard, J. M. Vose, A. D. Zelenetz et al., Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab, Blood, vol.105, issue.12, pp.4576-4582, 2005.

S. J. Horning, A. Younes, V. Jain, S. Kroll, J. Lucas et al., Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After Rituximab, Journal of Clinical Oncology, vol.23, issue.4, pp.712-719, 2005.

K. Hohloch, A. B. Delaloye, C. Windemuth-kieselbach, J. Gomez-codina, W. Linkesch et al., Radioimmunotherapy Confers Long-Term Survival to Lymphoma Patients with Acceptable Toxicity: Registry Analysis by the International Radioimmunotherapy Network, Journal of Nuclear Medicine, vol.52, issue.9, pp.1354-1360, 2011.

M. S. Czuczman, C. Emmanouilides, M. Darif, T. E. Witzig, L. I. Gordon et al., Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy, Journal of Clinical Oncology, vol.25, issue.27, pp.4285-4292, 2007.

R. I. Fisher, M. S. Kaminski, R. L. Wahl, S. J. Knox, A. D. Zelenetz et al., Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkin?s Lymphomas, Journal of Clinical Oncology, vol.23, issue.30, pp.7565-7573, 2005.

A. Shimoni, I. Avivi, J. M. Rowe, M. Yeshurun, I. Levi et al., A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma, Cancer, vol.118, issue.19, pp.4706-4714, 2012.

F. Morschhauser, J. Radford, A. Van-hoof, U. Vitolo, P. Soubeyran et al., Phase III Trial of Consolidation Therapy With Yttrium-90?Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma, Journal of Clinical Oncology, vol.26, issue.32, pp.5156-5164, 2008.

J. P. Leonard, M. Coleman, L. Kostakoglu, A. Chadburn, E. Cesarman et al., Abbreviated Chemotherapy With Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab for Untreated Follicular Lymphoma, Journal of Clinical Oncology, vol.23, issue.24, pp.5696-5704, 2005.

J. D. Hainsworth, D. R. Spigel, T. M. Markus, D. Shipley, D. Thompson et al., Rituximab plus Short-Duration Chemotherapy Followed by Yttrium-90 Ibritumomab Tiuxetan as First-Line Treatment for Patients with Follicular Non-Hodgkin Lymphoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium, Clinical Lymphoma and Myeloma, vol.9, issue.3, pp.223-228, 2009.

J. D. Hainsworth, D. R. Spigel, T. M. Markus, D. Shipley, D. Thompson et al., Rituximab plus Short-Duration Chemotherapy Followed by Yttrium-90 Ibritumomab Tiuxetan as First-Line Treatment for Patients with Follicular Non-Hodgkin Lymphoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium, Clinical Lymphoma and Myeloma, vol.9, issue.3, pp.223-228, 2009.

P. L. Zinzani, G. Rossi, S. Franceschetti, B. Botto, A. Di-rocco et al., Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients, Clinical Cancer Research, vol.16, issue.15, pp.3998-4004, 2010.

K. Hohloch, H. K. Lankeit, P. L. Zinzani, C. W. Scholz, M. Lorsbach et al., Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network, European Journal of Nuclear Medicine and Molecular Imaging, vol.41, issue.8, pp.1585-1592, 2014.

C. W. Scholz, A. Pinto, W. Linkesch, O. Lindén, A. Viardot et al., 90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial, Journal of Clinical Oncology, vol.31, issue.3, pp.308-313, 2013.

P. Mondello, S. Cuzzocrea, M. Navarra, and M. Mian, 90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity, Oncotarget, vol.7, issue.7, pp.7597-7609, 2015.

T. M. Illidge, Radioimmunotherapy of Lymphoma: A Treatment Approach Ahead of Its Time or Past Its Sell-By Date?, Journal of Clinical Oncology, vol.28, issue.18, pp.2944-2946, 2010.

R. M. Sharkey, A. Brenner, J. Burton, G. Hajjar, S. P. Toder et al., Radioimmunotherapy of non-Hodgkin' lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?, J Nucl Med, vol.44, issue.12, pp.2000-2018, 2003.

O. Lindén, C. Hindorf, E. Cavallin-ståhl, W. A. Wegener, D. M. Goldenberg et al., Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab, Clin Cancer Res, vol.11, issue.14, pp.5215-5237, 2005.

C. Bodet-milin, F. Kraeber-bodere, B. Dupas, F. Morschhauser, T. Gastinne et al., Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography, Haematologica, vol.93, issue.3, pp.390-397, 2008.

F. Morschhauser, F. Kraeber-bodéré, W. A. Wegener, J. Harousseau, M. Petillon et al., High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma, Journal of Clinical Oncology, vol.28, issue.23, pp.3709-3716, 2010.

R. M. Sharkey, O. W. Press, and D. M. Goldenberg, A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy, Blood, vol.113, issue.17, pp.3891-3895, 2009.

R. M. Sharkey, H. Karacay, C. R. Johnson, S. Litwin, E. A. Rossi et al., Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma, J Nucl Med, vol.50, issue.3, pp.444-53, 2009.

M. J. Mattes, R. M. Sharkey, H. Karacay, M. S. Czuczman, and D. M. Goldenberg, Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-anti-CD22 IgG (Epratuzumab) and Unlabeled Anti-CD20 IgG (Veltuzumab), Clinical Cancer Research, vol.14, issue.19, pp.6154-6160, 2008.

R. A. Kyle and S. V. Rajkumar, Multiple myeloma, N Engl J Med, vol.351, issue.18, pp.1860-73, 2004.
URL : https://hal.archives-ouvertes.fr/hal-00557757

A. Palumbo and K. Anderson, Multiple myeloma, N Engl J Med, vol.364, issue.11, pp.1046-60, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01282339

S. Lonial, C. S. Mitsiades, and P. G. Richardson, Treatment Options for Relapsed and Refractory Multiple Myeloma, Clinical Cancer Research, vol.17, issue.6, pp.1264-1277, 2011.

P. Kapoor, P. T. Greipp, W. G. Morice, S. V. Rajkumar, T. E. Witzig et al., Anti-CD20 monoclonal antibody therapy in multiple myeloma, Br J Haematol, vol.141, issue.2, pp.135-183, 2008.

F. K. Stevenson, A. J. Bell, R. Cusack, T. J. Hamblin, C. J. Slade et al., Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody, Blood, vol.77, issue.5, pp.1071-1079, 1991.

Y. W. Huang, J. A. Richardson, and E. S. Vitetta, Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells, Cancer Res, vol.55, issue.3, pp.610-616, 1995.

R. Stein, M. R. Smith, S. Chen, M. Zalath, and D. M. Goldenberg, Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines, Clin Cancer Res, vol.15, issue.8, pp.2808-2825, 2009.

T. Goto, S. J. Kennel, M. Abe, M. Takishita, M. Kosaka et al., A novel membrane antigen selectively expressed on terminally differentiated human B cells, Blood, vol.84, issue.6, pp.1922-1930, 1994.

S. Ozaki, M. Kosaka, Y. Wakahara, Y. Ozaki, M. Tsuchiya et al., Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells, Blood, vol.93, issue.11, pp.3922-3952, 1999.

F. Van-rhee, S. M. Szmania, M. Dillon, A. M. Van-abbema, X. Li et al., Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma, Mol Cancer Ther, vol.8, issue.9, pp.2616-2640, 2009.

R. Bataille, B. Barlogie, Z. Y. Lu, J. F. Rossi, T. Lavabre-bertrand et al., Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma, Blood, vol.86, issue.2, pp.685-691, 1995.

B. Klein, J. Wijdenes, X. G. Zhang, J. M. Boiron, J. M. Brochier et al., Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia, Blood, vol.78, issue.5, pp.1198-204, 1991.

C. Lee, B. Guinn, S. E. Brooks, D. Richardson, and K. Orchard, CD66a (CEACAM1) is the only CD66 variant expressed on the surface of plasma cells in multiple myeloma: a refined target for radiotherapy trials?, British Journal of Haematology, vol.149, issue.5, pp.795-796, 2010.

P. A. Erba, M. Sollini, E. Orciuolo, C. Traino, M. Petrini et al., Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies, J Nucl Med, vol.53, issue.6, pp.922-929, 2012.

C. Rousseau, L. Ferrer, S. Supiot, M. Bardies, F. Davodeau et al., Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients, Tumour Biol, vol.33, issue.3, pp.679-88, 2012.

N. Fichou, S. Gouard, C. Maurel, J. Barbet, L. Ferrer et al., Single-dose anti-CD138 radioimmunotherapy: bismuth-213 is more efficient than lutetium-177 for treatment of multiple myeloma in a preclinical model, Front Med, vol.2, issue.12, p.76, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01817464

D. J. Green, S. O?steen, Y. Lin, M. L. Comstock, A. L. Kenoyer et al., CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies, Blood, vol.131, issue.6, pp.611-620, 2018.

R. D. Sanderson and Y. Yang, Syndecan-1: a dynamic regulator of the myeloma microenvironment, Clinical & Experimental Metastasis, vol.25, issue.2, pp.149-159, 2007.

J. Wijdenes, W. C. Vooijs, C. Clément, J. Post, F. Morard et al., A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1, British Journal of Haematology, vol.94, issue.2, pp.318-323, 1996.

P. W. Derksen, R. M. Keehnen, L. M. Evers, M. H. Van-oers, M. Spaargaren et al., Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma, Blood, vol.99, issue.4, pp.1405-1410, 2002.

S. Supiot, A. Faivre-chauvet, O. Couturier, M. F. Heymann, N. Robillard et al., Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma, Cancer, vol.94, issue.S4, pp.1202-1209, 2002.

O. Couturier, A. Faivre-chauvet, I. V. Filippovich, P. Thédrez, C. Saï-maurel et al., Validation of 213Bi-alpha radioimmunotherapy for multiple myeloma, Clin Cancer Res, vol.5, pp.3165-70, 1999.

M. Malvezzi, P. Bertuccio, F. Levi, C. La-vecchia, and E. Negri, European cancer mortality predictions for the year 2013, Annals of Oncology, vol.24, issue.3, pp.792-800, 2013.

J. S. Lam, J. T. Leppert, S. N. Vemulapalli, O. Shvarts, and A. S. Belldegrun, Secondary Hormonal Therapy for Advanced Prostate Cancer, The Journal of Urology, vol.175, issue.1, p.27???34, 2006.

I. F. Tannock, R. De-wit, W. R. Berry, J. Horti, A. Pluzanska et al., Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer, New England Journal of Medicine, vol.351, issue.15, pp.1502-1512, 2004.

D. P. Petrylak, C. M. Tangen, M. H. Hussain, P. N. Lara, J. A. Jones et al., Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer, New England Journal of Medicine, vol.351, issue.15, pp.1513-1520, 2004.

S. Chiacchio, S. Mazzarri, A. Lorenzoni, N. Nyakale, G. Boni et al., Radionuclide therapy and integrated protocols for bone metastases, Q J Nucl Med Mol Imaging, vol.55, issue.4, pp.431-478, 2011.

S. T. Tagawa, H. Beltran, S. Vallabhajosula, S. J. Goldsmith, J. Osborne et al., Anti-prostate-Specific membrane antigen-based radioimmunotherapy for prostate cancer, Cancer, vol.116, issue.S4, pp.1075-1083, 2010.

R. T. O'donnell, S. J. Denardo, L. A. Miers, K. R. Lamborn, D. L. Kukis et al., Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and90yttrium-DOTA-peptide-ChL6, The Prostate, vol.50, issue.1, pp.27-37, 2001.

C. M. Richman, S. J. Denardo, O. Donnell, R. T. Yuan, A. Shen et al., High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody, Clinical Cancer Research, vol.11, issue.16, pp.5920-5927, 2005.

R. F. Meredith, M. B. Khazaeli, G. Plott, A. J. Bueschen, R. H. Wheeler et al., Radioimmunotherapy for metastatic prostate cancer using a high affinity antibody, International Journal of Radiation Oncology*Biology*Physics, vol.27, issue.6, p.318, 1993.

R. L. Sokoloff, K. C. Norton, C. L. Gasior, K. M. Marker, and L. S. Grauer, A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine, The Prostate, vol.43, issue.2, pp.150-157, 2000.

G. L. Wright, C. Haley, M. L. Beckett, and P. F. Schellhammer, Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues, Urologic Oncology: Seminars and Original Investigations, vol.1, issue.1, pp.18-28, 1995.

R. S. Israeli, C. T. Powell, J. G. Corr, W. R. Fair, and W. D. Heston, Expression of the prostate-specific membrane antigen, Cancer Res, vol.54, issue.7, pp.1807-1818, 1994.

R. S. Israeli, C. T. Powell, W. R. Fair, and W. D. Heston, Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen, Cancer Res, vol.53, issue.2, pp.227-257, 1993.

J. S. Horoszewicz, E. Kawinski, and G. P. Murphy, 5162504 Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients, Biotechnology Advances, vol.11, issue.2, p.352, 1993.

D. G. Bostwick, A. Pacelli, M. Blute, P. Roche, and G. P. Murphy, Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma, Cancer, vol.82, issue.11, pp.2256-2261, 1998.

H. Liu, A. K. Rajasekaran, P. Moy, Y. Xia, S. Kim et al., Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy, Cancer Res, vol.58, issue.18, pp.4055-60

H. Liu, P. Moy, S. Kim, Y. Xia, A. Rajasekaran et al., Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium, Cancer Res, vol.57, issue.17, pp.3629-3663, 1997.

M. I. Milowsky, D. M. Nanus, L. Kostakoglu, S. Vallabhajosula, S. J. Goldsmith et al., Phase I Trial of Yttrium-90?Labeled Anti?Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Androgen-Independent Prostate Cancer, Journal of Clinical Oncology, vol.22, issue.13, pp.2522-2531, 2004.

N. H. Bander, M. I. Milowsky, D. M. Nanus, L. Kostakoglu, S. Vallabhajosula et al., Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer, Journal of Clinical Oncology, vol.23, issue.21, pp.4591-4601, 2005.

A. I. Kassis and S. J. Adelstein, Therapeutic Radionuclides: Biophysical and Radiobiologic Principles, Seminars in Nuclear Medicine, vol.38, issue.5, pp.358-366, 2008.

M. R. Raju, Y. Eisen, S. Carpenter, K. Jarrett, and W. F. Harvey, Radiobiology of ? Particles. IV. Cell Inactivation by ? Particles of Energies 0.4-3.5 MeV, Radiation Research, vol.133, issue.3, p.289, 1993.

J. C. Roeske, M. R. Mcdevitt, S. Palm, B. J. Allen, A. B. Brill et al., MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alphaparticle emitters for targeted radionuclide therapy, J Nucl Med, vol.51, issue.2, pp.311-339, 2010.

C. Featherstone, ?-Particle-emitting radioisotopes coupled to antibody for acute myeloid leukaemia treatment, Molecular Medicine Today, vol.3, issue.6, pp.232-233, 1997.

U. B. Hagemann, D. Mihaylova, S. R. Uran, J. Borrebaek, D. Grant et al., Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma, Oncotarget, vol.8, issue.34, pp.56311-56326, 2017.

E. M. Link, Targeting Melanoma with 211 At/131I-Methylene Blue: Preclinical and Clinical Experience, Hybridoma, vol.18, issue.1, pp.77-82, 1999.

E. Cederkrantz, H. Andersson, P. Bernhardt, T. Bäck, R. Hultborn et al., Absorbed Doses and Risk Estimates of 211At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients, International Journal of Radiation Oncology*Biology*Physics, vol.93, issue.3, pp.569-576, 2015.

T. D. Poeppel, D. Handkiewicz-junak, M. Andreeff, A. Becherer, A. Bockisch et al., EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer, European Journal of Nuclear Medicine and Molecular Imaging, vol.45, issue.5, pp.824-845, 2017.

R. Coleman, Treatment of Metastatic Bone Disease and the Emerging Role of Radium-223, Seminars in Nuclear Medicine, vol.46, issue.2, pp.99-104, 2016.

A. Takalkar, B. Paryani, S. Adams, and V. Subbiah, Radium-223 dichloride therapy in breast cancer with osseous metastases, BMJ Case Reports, vol.2015, issue.nov17 2, pp.bcr2015211152-bcr2015211152, 2015.

M. Chérel, F. Davodeau, F. Kraeber-bodéré, and J. F. Chatal, Current status and perspectives in alpha radioimmunotherapy, Q J Nucl Med Mol Imaging, vol.50, issue.4, pp.322-331, 2006.

C. Apostolidis, R. Molinet, J. Mcginley, K. Abbas, J. Möllenbeck et al., Cyclotron production of Ac-225 for targeted alpha therapy11Dedicated to Prof. Dr. Franz Baumgärtner on the occasion of his 75th birthday., Applied Radiation and Isotopes, vol.62, issue.3, pp.383-387, 2005.

F. Haddad, J. Barbet, and J. Chatal, The ARRONAX Project, Current Radiopharmaceuticalse, vol.4, issue.3, pp.186-196, 2011.

R. F. Hobbs, H. Song, D. L. Huso, M. H-sundel, and G. Sgouros, A nephron-based model of the kidneys for macro-to-micro ?-particle dosimetry, Physics in Medicine and Biology, vol.57, issue.13, pp.4403-4424, 2012.

R. F. Hobbs, H. Song, C. J. Watchman, W. E. Bolch, A. Aksnes et al., A bone marrow toxicity model for223Ra alpha-emitter radiopharmaceutical therapy, Physics in Medicine and Biology, vol.57, issue.10, pp.3207-3222, 2012.

E. Kebebew, P. H. Ituarte, A. E. Siperstein, Q. Duh, and O. H. Clark, Medullary thyroid carcinoma, Cancer, vol.88, issue.5, pp.1139-1148, 2000.

R. Elisei, B. Cosci, C. Romei, V. Bottici, G. Renzini et al., Prognostic Significance of SomaticRETOncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.3, pp.682-687, 2008.

L. E. Tisell, A. Oden, A. Muth, G. Altiparmak, J. Mõlne et al., The Ki67 index a prognostic marker in medullary thyroid carcinoma, British Journal of Cancer, vol.89, issue.11, pp.2093-2097, 2003.

Y. Ito, H. Yoshida, C. Tomoda, T. Uruno, Y. Takamura et al., Expression of cdc25B and cdc25A in medullary thyroid carcinoma: cdc25B expression level predicts a poor prognosis, Cancer Letters, vol.229, issue.2, pp.291-297, 2005.

E. Fialkowski, M. Debenedetti, and J. Moley, Long-term Outcome of Reoperations for Medullary Thyroid Carcinoma, World Journal of Surgery, vol.32, issue.5, pp.754-765, 2008.

J. Barbet, L. Campion, F. Kraeber-bodéré, and J. Chatal, Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid Carcinoma, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.11, pp.6077-6084, 2005.

L. Giraudet, A. , G. Al, A. Aupérin, A. Leboulleux et al., Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times, Eur J Endocrinol, vol.158, issue.2, pp.239-285, 2008.

J. W. De-groot, B. A. Zonnenberg, P. Q. Van-ufford-mannesse, M. M. De-vries, T. P. Links et al., A Phase II Trial of Imatinib Therapy for Metastatic Medullary Thyroid Carcinoma, The Journal of Clinical Endocrinology & Metabolism, vol.92, issue.9, pp.3466-3469, 2007.

K. Frank-raue, M. Fabel, S. Delorme, U. Haberkorn, and F. Raue, Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma, European Journal of Endocrinology, vol.157, issue.2, pp.215-220, 2007.

E. T. Lam, M. D. Ringel, R. T. Kloos, T. W. Prior, M. V. Knopp et al., Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer, Journal of Clinical Oncology, vol.28, issue.14, pp.2323-2330, 2010.

M. J. Schlumberger, R. Elisei, L. Bastholt, L. J. Wirth, R. G. Martins et al., Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer, Journal of Clinical Oncology, vol.27, issue.23, pp.3794-3801, 2009.

S. A. Wells, J. E. Gosnell, R. F. Gagel, J. Moley, D. Pfister et al., Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer, Journal of Clinical Oncology, vol.28, issue.5, pp.767-772, 2010.

S. A. Wells, B. G. Robinson, R. F. Gagel, H. Dralle, J. A. Fagin et al., Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA)., Journal of Clinical Oncology, vol.28, issue.15_suppl, pp.5503-5503, 2010.

M. E. Juweid, G. Hajjar, L. C. Swayne, R. M. Sharkey, S. Suleiman et al., Phase I/II trial of131I-MN-14 F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma, Cancer, vol.85, issue.8, pp.1828-1842, 1999.

M. E. Juweid, G. Hajjar, L. C. Swayne, R. M. Sharkey, S. Suleiman et al., Phase I/II trial of131I-MN-14 F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma, Cancer, vol.85, issue.8, pp.1828-1842, 1999.

R. M. Sharkey and D. M. Goldenberg, Perspectives on cancer therapy with radiolabeled monoclonal antibodies, J Nucl Med, vol.46, issue.1, pp.115-142, 2005.

J. M. Le-doussal, E. Gautherot, A. Gruaz-guyon, M. Martin, M. Delaage et al., Targeting of melanoma cells via biospecific antibodies (Bs-MAbs), Melanoma Research, vol.3, issue.1, p.19, 1993.

J. Barbet, M. Bardiès, M. Bourgeois, J. Chatal, M. Chérel et al., Radiolabeled Antibodies for Cancer Imaging and Therapy, Antibody Engineering, vol.907, pp.681-697, 2012.

D. M. Goldenberg, R. M. Sharkey, G. Paganelli, J. Barbet, and J. Chatal, Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy, Journal of Clinical Oncology, vol.24, issue.5, pp.823-834, 2006.

J. Barbet, F. Kraeber-bodéré, J. Vuillez, E. Gautherot, É. Rouvier et al., Pretargeting with the Affinity Enhancement System for Radioimmunotherapy, Cancer Biotherapy and Radiopharmaceuticals, vol.14, issue.3, pp.153-166, 1999.

F. Kraeber-bodéré, S. Bardet, C. A. Hoefnagel, M. R. Vieira, J. P. Vuillez et al., Retraction: ?Radioimmunotherapy of small-volume disease of metastatic colorectal cancer: Results of a phase II trial with the iodine-131-labeled humanized anti-carcinoembryonic antigen antibody hMN-14,?, Cancer, vol.121, issue.13, pp.2290-2290, 2015.

F. Kraeber-bodéré, A. Faibre-chauvet, C. Saï-maurel, E. Gautherot, M. Fiche et al., Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft, J Nucl Med, vol.40, issue.1, pp.198-204, 1999.

J. Chatal, L. Campion, F. Kraeber-bodéré, S. Bardet, J. Vuillez et al., Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti?Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group, Journal of Clinical Oncology, vol.24, issue.11, pp.1705-1711, 2006.

P. Salaun, L. Campion, C. Bournaud, A. Faivre-chauvet, J. Vuillez et al., Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement, Journal of Nuclear Medicine, vol.53, issue.8, pp.1185-1192, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00932253

D. M. Goldenberg, E. A. Rossi, R. M. Sharkey, W. J. Mcbride, and C. Chang, Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting, Journal of Nuclear Medicine, vol.49, issue.1, pp.158-163, 2007.

E. A. Rossi, D. M. Goldenberg, T. M. Cardillo, W. J. Mcbride, R. M. Sharkey et al., Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting, Proceedings of the National Academy of Sciences, vol.103, issue.18, pp.6841-6846, 2006.

R. M. Sharkey, E. A. Rossi, W. J. Mcbride, C. Chang, and D. M. Goldenberg, Recombinant Bispecific Monoclonal Antibodies Prepared by the Dock-and-Lock Strategy for Pretargeted Radioimmunotherapy, Seminars in Nuclear Medicine, vol.40, issue.3, pp.190-203, 2010.

R. Schoffelen, W. T. Van-der-graaf, G. Franssen, R. M. Sharkey, D. M. Goldenberg et al., Pretargeted 177Lu Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colonic Tumors in Mice, Journal of Nuclear Medicine, vol.51, issue.11, pp.1780-1787, 2010.

R. Schoffelen, W. Woliner-van-der-weg, E. P. Visser, D. M. Goldenberg, R. M. Sharkey et al., Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer, European Journal of Nuclear Medicine and Molecular Imaging, vol.41, issue.8, pp.1593-602, 2014.

C. Bodet-milin, L. Ferrer, A. Rauscher, D. Masson, L. Rbah-vidal et al., Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients, Frontiers in Medicine, vol.2, issue.6, p.84, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01258870

S. Stute, D. Benoit, A. Martineau, N. S. Rehfeld, and I. Buvat, A method for accurate modelling of the crystal response function at a crystal sub-level applied to PET reconstruction, Physics in Medicine and Biology, vol.56, issue.3, pp.793-809, 2011.

W. W. Moses, C. Granja, and C. Leroy, Recent Advances and Future Advances in Time-of-Flight PET, Nucl Instrum Methods Phys Res A, vol.580, issue.2, pp.919-943, 2010.

T. K. Lewellen, Recent developments in PET detector technology, Physics in Medicine and Biology, vol.53, issue.17, pp.R287-R317, 2008.

S. M. Knowles and A. M. Wu, Advances in Immuno?Positron Emission Tomography: Antibodies for Molecular Imaging in Oncology, Journal of Clinical Oncology, vol.30, issue.31, pp.3884-3892, 2012.

O. C. Boerman and W. J. Oyen, Immuno-PET of Cancer: A Revival of Antibody Imaging, Journal of Nuclear Medicine, vol.52, issue.8, pp.1171-1172, 2011.

G. A. Van-dongen, G. W. Visser, M. N. Lub?de-hooge, E. G. De-vries, and L. R. Perk, Immuno?PET: A Navigator in Monoclonal Antibody Development and Applications, The Oncologist, vol.12, issue.12, pp.1379-1389, 2007.

S. Heskamp, H. W. Van-laarhoven, J. D. Molkenboer-kuenen, G. M. Franssen, Y. M. Versleijen-jonkers et al., ImmunoSPECT and ImmunoPET of IGF-1R Expression with the Radiolabeled Antibody R1507 in a Triple-Negative Breast Cancer Model, Journal of Nuclear Medicine, vol.51, issue.10, pp.1565-1572, 2010.

R. P. Baum, V. Prasad, D. Muller, C. Schuchardt, A. Orlova et al., Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules, Journal of Nuclear Medicine, vol.51, issue.6, pp.892-897, 2010.

W. J. Mcbride, R. M. Sharkey, H. Karacay, C. A. D'souza, E. A. Rossi et al., A Novel Method of 18F Radiolabeling for PET, Journal of Nuclear Medicine, vol.50, issue.6, pp.991-998, 2009.

W. J. Mcbride, P. Zanzonico, R. M. Sharkey, C. Norén, H. Karacay et al., Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide, J Nucl Med, vol.47, issue.10, pp.1678-88, 2006.

R. Schoffelen, R. M. Sharkey, D. M. Goldenberg, G. Franssen, W. J. Mcbride et al., Pretargeted Immuno?Positron Emission Tomography Imaging of Carcinoembryonic Antigen?Expressing Tumors with a Bispecific Antibody and a68Ga- and18F-Labeled Hapten Peptide in Mice with Human Tumor Xenografts, Molecular Cancer Therapeutics, vol.9, issue.4, pp.1019-1027, 2010.

P. Börjesson, Y. Jauw, R. Boellaard, R. De-bree, E. Comans et al., Performance of Immuno-Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer Patients, Clinical Cancer Research, vol.12, issue.7, pp.2133-2140, 2006.

L. R. Perk, M. Stigter-van-walsum, G. W. Visser, R. W. Kloet, M. J. Vosjan et al., Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30, European Journal of Nuclear Medicine and Molecular Imaging, vol.35, issue.10, pp.1857-1867, 2008.

C. R. Divgi, R. G. Uzzo, C. Gatsonis, R. Bartz, S. Treutner et al., Positron Emission Tomography/Computed Tomography Identification of Clear Cell Renal Cell Carcinoma: Results From the REDECT Trial, Journal of Clinical Oncology, vol.31, issue.2, pp.187-194, 2013.

C. R. Divgi, N. Pandit-taskar, A. A. Jungbluth, V. E. Reuter, M. Gönen et al., Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial, The Lancet Oncology, vol.8, issue.4, pp.304-310, 2007.

D. A. Pryma, J. A. O'donoghue, J. L. Humm, A. A. Jungbluth, L. J. Old et al., Correlation of In Vivo and In Vitro Measures of Carbonic Anhydrase IX Antigen Expression in Renal Masses Using Antibody 124I-cG250, Journal of Nuclear Medicine, vol.52, issue.4, pp.535-540, 2011.

C. Rousseau, A. Ruellan, K. Bernardeau, F. Kraeber-bodéré, S. Gouard et al., Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors, EJNMMI Research, vol.1, issue.1, p.20, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00626326

E. C. Dijkers, O. Munnink, T. H. Kosterink, J. G. Brouwers, A. H. Jager et al.,

E. C. Dijkers, T. H. Oude-munnink, J. G. Kosterink, A. H. Brouwers, P. L. Jager et al., Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer, Clinical Pharmacology & Therapeutics, vol.87, issue.5, pp.586-592, 2010.

M. L. Rothenberg, D. P. Carbone, and D. H. Johnson, Improving the evaluation of new cancer treatments: challenges and opportunities, Nature Reviews Cancer, vol.3, issue.4, pp.303-309, 2003.

J. A. Carrasquillo, N. Pandit-taskar, O. 'donoghue, J. A. Humm, J. L. Zanzonico et al.,

J. A. Carrasquillo, N. Pandit-taskar, J. A. O'donoghue, J. L. Humm, P. Zanzonico et al., 124I-huA33 Antibody PET of Colorectal Cancer, Journal of Nuclear Medicine, vol.52, issue.8, pp.1173-1180, 2011.

I. Verel, G. W. Visser, M. J. Vosjan, R. Finn, R. Boellaard et al., High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy, European Journal of Nuclear Medicine and Molecular Imaging, vol.31, issue.12, pp.1645-1652, 2004.

L. R. Perk, O. J. Visser, M. Stigter-van-walsum, M. J. Vosjan, G. W. Visser et al., Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography, European Journal of Nuclear Medicine and Molecular Imaging, vol.33, issue.11, pp.1337-1345, 2006.

M. R. Zalutsky, Potential of Immuno-Positron Emission Tomography for Tumor Imaging and Immunotherapy Planning, Clinical Cancer Research, vol.12, issue.7, pp.1958-1960, 2006.

W. B. Nagengast, M. N. Lub-de-hooge, S. F. Oosting, W. F. Den-dunnen, F. Warnders et al., VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment, Cancer Research, vol.71, issue.1, pp.143-153, 2010.

S. David, D. Visvikis, C. Roux, and M. Hatt, Multi-observation PET image analysis for patient follow-up quantitation and therapy assessment, Physics in Medicine and Biology, vol.56, issue.18, pp.5771-5788, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00707280